{
    "ucits": true,
    "type": "ETF",
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": "None",
    "classification": "non-complex",
    "supporting_data": "The VanEck Bionic Engineering UCITS ETF is a UCITS-compliant ETF, which is automatically presumed non-complex under MiFID II unless it contains features that make its structure, risks, or payoff difficult for retail investors to understand[1]. The fund's primary strategy is physical replication of the MVISu00ae Global Bionic Healthcare ESG Index, investing directly in the underlying equity securities of the index. While the fund may use financial derivative instruments (FDIs) such as futures, options, and swaps for efficient portfolio management (EPM) and to replicate the index where physical replication is not practical or cost-efficient, the use of derivatives is not central to the investment objective and is limited in scope. The fund does not employ significant leverage, does not use synthetic replication, and does not embed complex derivatives or structured products. The risks disclosed (market risk, liquidity risk, sector concentration) are typical of equity ETFs and do not introduce structural complexity beyond what is standard for physically replicated UCITS ETFs. The fund's structure, objective, and risk profile are transparent and can be readily understood by a retail investor with basic knowledge. No features were identified that would override the UCITS presumption of non-complexity under MiFID II[1][2]."
}